The diabetic foot ulcers treatment market involves products such as wound care dressings, wound care devices, active therapies, and others. These products aid in wound healing and prevent wound deterioration. Diabetic foot ulcers occur due to long-term damage to blood vessels and nerves caused by diabetes. If left untreated, these ulcers can become severely infected and may require limb amputation. Therefore, effective treatment of these ulcers is crucial. The global diabetic foot ulcers treatment market is estimated to be valued at US$ 7.72 Bn in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the diabetic foot ulcers treatment are 3M Healthcare, Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, Molnlycke Health Care AB, Alkem Laboratories Ltd., Healthium Medtech, Kerecis, Podimetrics, Carmell Corporation, Paracrine, Inc., VIVEX Biologics, Inc., and PolarityTE, Inc. The market provides opportunities for market expansion through new product launches and geographical expansion to untapped emerging economies. Major players are focusing on global expansion by adopting strategies such as mergers, acquisitions, partnerships and collaborations.

The rising geriatric population is considered as a major driver for the growth of the diabetic foot ulcers treatment market. With increasing aging, the prevalence of diabetes and associated diabetic foot ulcers is also steadily increasing. According to the United Nations, the number of people over 60 years is projected to double from 12% to 22% between 2015 and 2050. Therefore, rising geriatric population presents lucrative growth opportunities for players in the diabetic foot ulcers treatment market. Other major drivers include increasing diabetic population globally, growing awareness about treatment options and favorable reimbursement scenario for wound care treatment in developed regions.

PEST Analysis

Political: Healthcare policies and regulations such as reimbursement policies, approval of new drugs/therapies influence market growth of diabetic foot ulcer treatment products.

Economic: Rising demand for cost-effective treatment options driving market growth amid growing healthcare costs due to increasing diabetic population globally.

Social: Increasing awareness about foot complications in diabetes and availability of new treatment options influencing positively. Sedentary lifestyles increasing risks of diabetes.

Technological: Developments in biologics, advanced wound dressings, regenerative therapies and monitoring devices fuel market growth. E-health solutions help improve access and compliance.

The geographical regions where the market in terms of value is concentrated are North America and Europe due to developed healthcare infrastructure, availability of reimbursements and more awareness among patients and physicians about available treatment options.

Asia Pacific region represents the fastest growing market for diabetic foot ulcer treatment due to increasing prevalence of diabetes, growing medical tourism industry and improving access to healthcare in countries like India, China and others. Rise in per capita incomes are also enabling patients afford expensive treatment options.

Most prevalent in the US and Germany, and growing rapidly in China and India due to increasing burden of diabetes in these nations. Products from US and European firms remain top choices due to reputation of these brands for quality.